Novel Engineered Microgels with Amphipathic Network Structures for Simultaneous Tumor and Inflammation Depression

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Nanotechnology

Background:

• Developing effective combination therapies for cancer and inflammation is challenging.
• Existing drug delivery systems often struggle with simultaneous release of hydrophilic and hydrophobic drugs.
• Amphipathic nanostructures offer potential for dual-drug delivery.

Purpose of the Study:

• To design and synthesize novel engineered microgels with amphipathic network structures.
• To evaluate the microgels' capacity for simultaneous loading and release of hydrophilic (diclofenac sodium) and hydrophobic (doxorubicin) drugs.
• To assess the in vivo efficacy and safety of dual-drug-loaded microgels for combination therapy.

Main Methods:

• Copolymerization of N-isopropylacrylamide, 1-vinylimidazole, and 2-(cinnamoyloxy)ethyl methacrylate.
• Characterization of microgel structure, drug loading, and release kinetics.
• In vitro cytotoxicity and cellular uptake studies.
• In vivo studies in animal models to evaluate antitumor efficacy and inflammation depression.

Main Results:

• Successfully synthesized engineered microgels with distinct hydrophilic and hydrophobic domains.
• Demonstrated efficient simultaneous loading and controlled release of diclofenac sodium and doxorubicin.
• Microgels exhibited excellent stability, low cytotoxicity, and prolonged blood circulation.
• In vivo studies confirmed simultaneous antitumor treatment and inflammation suppression with high efficacy and low toxicity.

Conclusions:

• Engineered amphipathic microgels are effective carriers for dual-drug combination therapy.
• These microgels offer a promising platform for simultaneous treatment of cancer and inflammation.
• The developed system demonstrates potential for improved therapeutic outcomes with reduced side effects.